STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Assembly Biosciences, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Farallon-affiliated investment vehicles and related persons reported aggregate ownership of 1,140,510 shares of Assembly Biosciences (ASMB), representing the position disclosed across the filing. The group also holds 510,205 Class A Warrants (currently exercisable subject to a 4.99% beneficial ownership limitation) and 510,205 Class B Warrants (exercisable beginning on a future date), for a total of 1,020,410 warrants that could convert into additional shares subject to the limitation.

The Schedule 13G is filed under the passive-investor provision, and the filers state the warrants are assumed not exercisable within 60 days for beneficial-ownership calculations. The filing lists the Farallon Funds, their general partners, and numerous individual Farallon managers as reporting persons and discloses shared voting and dispositive power over the reported shares.

Positive
  • Aggregate disclosed stake of 1,140,510 shares provides clear, material ownership transparency
  • Substantial warrant holdings (1,020,410 total) are disclosed, showing potential future share conversion
  • Filing under Schedule 13G (passive) and an explicit certification that holdings are not intended to influence control
Negative
  • None.

Insights

TL;DR: Farallon disclosed a meaningful passive stake in ASMB with substantial warrant exposure, limited by a 4.99% ownership cap.

The filing shows the Farallon group holds 1,140,510 shares and 1,020,410 warrants convertible into shares subject to a contractual Beneficial Ownership Limitation of 4.99%. Because the report is filed under the passive Schedule 13G route, the group affirms the position is not held to influence control. For investors, the combination of direct shares plus warrants signals potential incremental demand for shares if warrants become exercisable and the ownership cap permits further conversion, but the current beneficial-ownership calculation excludes the warrants due to timing and the 60-day exercisability assumption.

TL;DR: Robust disclosure of ownership structure and reliance on passive-investor classification reduces immediate governance concerns.

The Schedule 13G identifies multiple fund entities, their general partners, and 17 individual Farallon managers as reporting persons, with the filers explicitly stating a passive intent. The filing clarifies shared voting/dispositive power across funds and disclaims affirmative group formation while attaching a joint acquisition statement. From a governance perspective, this level of transparency and the passive filing status suggest no immediate coordination to change control, though the presence of sizable shared positions warrants monitoring for any future Section 13D amendments.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/15/2025
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/15/2025
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/15/2025
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/15/2025
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/15/2025
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/15/2025
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/15/2025
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/15/2025
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

FAQ

How many Assembly Biosciences (ASMB) shares does Farallon report owning?

The filers report aggregate ownership of 1,140,510 shares of ASMB.

Does Farallon hold warrants that could convert into ASMB shares?

Yes. The filing discloses 510,205 Class A Warrants and 510,205 Class B Warrants, totaling 1,020,410 warrants that may convert into shares subject to a beneficial ownership cap.

What ownership percentage does the filing show for the reporting persons?

Individual cover pages show percentages such as 7.3% for certain reporting persons and 7% for the Farallon Partners entity, with other funds reporting smaller percentages; the aggregate positions are disclosed on each cover page.

Are the warrants counted in the beneficial ownership total?

No. The Reporting Persons state they assumed the warrants are not exercisable within 60 days and therefore did not include them in the reported beneficial ownership due to the 4.99% Beneficial Ownership Limitation.

Under which rule was this Schedule 13G filed?

The filing states it was submitted pursuant to Section 240.13d-1(c), the passive-investor provision.
Assembly Bioscie

NASDAQ:ASMB

ASMB Rankings

ASMB Latest News

ASMB Latest SEC Filings

ASMB Stock Data

580.96M
10.11M
38.52%
25.43%
11.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO